THE NICHOLAS CONOR INSTITUTE
Curing Kids Cancer Through Collaboration
Curing Kids Cancer Through Collaboration
"We believe this partnership will accelerate our goal of enabling real-time bench-to-bedside medicine - providing results for today's patients based on personalized analysis while culling the learnings to apply to other patients." -Raphael Lehrer, Ph.D., President and Chief Scientist of GeneKey
- Research the causes of cancers with specific focus on discovering cancer-specific therapeutic and diagnostic targets
- Discover, validate and develop markers that will guide the physician to select individualized therapies
- Develop a molecular profiling platform to monitor cancer and patient physiology allowing rational guidance of therapies
- Monitor the efficacy and toxicity of therapies in childhood, adolescent and young adult cancer patients
|
AltheaDx is bringing theranostics into clinical use. Our labs are located in a 20,000 sq. ft. building in San Diego, California, with service operations for biopharma customers in compliance with GLP and CLIA requirements. The company has several key patents and technology affiliations with a variety of industry and academic institutions, including: NIH, NCI, UCSD, Sidney Kimmel Cancer Center, MD Anderson, and Memorial Sloan Kettering. We have a track record of reducing the time, risk, and cost of drug development by providing biomarker discovery and development to biopharma clients and clinical testing services to physicians. Our proprietary gene expression profiles include quantitative assays for diagnosis of pediatric cancers, specifically Small Round Blue Cell Tumors that are often difficult to differentiate. Our goal is to fully validate these tests through industry collaborations and to make them widely available for diagnosis and treatment of these rare diseases. We see great opportunity in working with TNCI to bring both awareness and resources for further development and validation of quantitative diagnostic tests. Through collaboration, AltheaDx will identify key partners and critical resources to enable utility of appropriate tests for diagnosis and treatment of childhood cancers. AltheaDx’ commitment to diagnostics excellence combined with TNCI’s focus will ultimately help in translation of clinically useful information for physicians and patients alike. AltheaDx has been working with the NIH on diagnostic tests for childhood cancers for over three years. This effort has resulted in published data and notice of approval from many in the industry, including the Children’s Oncology Group. However, the test is still not broadly available. We believe that TNCI’s commitment and awareness campaign will help deliver the much needed resources and clinical samples that are required to launch this test nationally. GeneKey
Genekey and The Nicholas Conor Institute are excited to announce a partnership to apply GeneKey’s personalized research approach to childhood cancers. As part of this partnership, patients will receive personalized therapy based upon the best available science, and researchers will continuously test and refine their models of childhood cancer biology and therapeutics based on the resulting clinical responses.
GeneKey offers a unique personalized research program that helps guide therapy decisions for cancer patients and their oncologists based on the molecular and genomic characteristics of their specific cancer. Our researchers use state-of-the-art genomic technologies as well as proprietary bio-computational tools to extract molecular information from patient biopsies, and then conduct full mechanistic analyses to potentially link a specific cancer to particular mechanisms and then to relevant therapies. Unlike other approaches in personalized medicine that focus on a limited set of cancer drugs, we look at hundreds of marketed drugs as well as investigational drugs for a potential match to patients’ specific cancer. "GeneKey is honored to partner with The Nicholas Conor Institute to battle the scourge of childhood cancer. We are very impressed with The Nicholas Conor Institute’s business and scientific approach to identify and develop both innovative therapies and original diagnostics for childhood cancer. We believe this partnership will accelerate our goal of enabling real-time bedside-to-bench medicine - providing results for today's patients based on personalized analysis while culling the learnings to apply to other patients."
- Raphael Lehrer, Ph.D., President and Chief Scientist
THE NICHOLAS CONOR INSTITUTE |